MCID: CRV033
MIFTS: 41

Cervical Adenosquamous Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenosquamous Carcinoma

MalaCards integrated aliases for Cervical Adenosquamous Carcinoma:

Name: Cervical Adenosquamous Carcinoma 12 15 73
Adenosquamous Cell Carcinoma of the Cervix Uteri 12
Adenosquamous Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5636
NCIt 50 C4519
UMLS 73 C0346202

Summaries for Cervical Adenosquamous Carcinoma

Disease Ontology : 12 A cervical carcinoma that derives from squamous cells and gland-like cells.

MalaCards based summary : Cervical Adenosquamous Carcinoma, also known as adenosquamous cell carcinoma of the cervix uteri, is related to adenocarcinoma and glassy cell variant cervical adenosquamous carcinoma. An important gene associated with Cervical Adenosquamous Carcinoma is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are Human cytomegalovirus infection and Focal Adhesion. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and kidney, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cervical Adenosquamous Carcinoma

Diseases related to Cervical Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 29.6 CDKN2A EGFR KDR PTGS2
2 glassy cell variant cervical adenosquamous carcinoma 12.6
3 adenosquamous carcinoma 10.5
4 pulmonary vein stenosis 10.2 KDR PDGFRA
5 hidradenoma 10.2 KRT7 MAML2
6 benign breast adenomyoepithelioma 10.2 EGFR KRT7
7 cervix carcinoma 10.2
8 spinal chordoma 10.2 EGFR KDR PDGFRA
9 oncocytic breast carcinoma 10.2 EGFR KRT7
10 lacrimal gland mucoepidermoid carcinoma 10.2 CRTC1 MAML2
11 solid adenocarcinoma with mucin production 10.2 KRT7 MUC6
12 nephrogenic adenoma of urinary bladder 10.2 KRT7 PAX8
13 nephrogenic adenoma 10.2 KRT7 PAX8
14 krukenberg carcinoma 10.2 HNF1B KRT7
15 bladder benign neoplasm 10.2 KRT7 PAX8
16 duodenum adenocarcinoma 10.2 KRT7 MUC6
17 breast mucoepidermoid carcinoma 10.1 CRTC1 MAML2
18 bile duct cystadenocarcinoma 10.1 KRT7 MUC6
19 endosalpingiosis 10.1 KRT7 PAX8
20 sensory organ benign neoplasm 10.1 KRT7 PAX8
21 appendix disease 10.1 KRT7 MUC6
22 adenomyoma 10.1 KRT7 MUC6
23 clear cell adenofibroma 10.1 KRT7 PDGFRA
24 recurrent respiratory papillomatosis 10.1 EGFR PTGS2
25 cavernous hemangioma 10.1 KDR KRT7 PDGFRA
26 polyposis syndrome, hereditary mixed, 1 10.1 MUC6 PTGS2
27 pleomorphic carcinoma 10.1 EGFR KRT7
28 bronchiolo-alveolar adenocarcinoma 10.1 EGFR KRT7 MUC6
29 horseshoe kidney 10.1 EGFR HNF1B KRT7
30 bursitis 10.1 KDR PTGS2
31 peritoneum cancer 10.1 KRT7 PAX8
32 oral cavity cancer 10.1 CRTC1 EGFR MAML2
33 kidney benign neoplasm 10.1 KRT7 PAX8
34 malignant peritoneal mesothelioma 10.1 CDKN2A EGFR
35 anaplastic oligodendroglioma 10.0 CDKN2A EGFR
36 clear cell hidradenoma 10.0 CRTC1 MAML2 PAX8
37 urethral diverticulum 10.0 KRT7 PAX8
38 clear cell adenocarcinoma 10.0 HNF1B KRT7 PAX8
39 ovarian cancer 1 10.0 HNF1B KRT7 PAX8
40 malignant ovarian surface epithelial-stromal neoplasm 10.0 HNF1B KRT7 PAX8
41 ovary epithelial cancer 10.0 HNF1B KRT7 PAX8
42 mucinous tubular and spindle renal cell carcinoma 10.0 KRT7 MUC6
43 renal pelvis adenocarcinoma 10.0 HCK KRT7 PAX8
44 stomach disease 10.0 EGFR MUC6 PTGS2
45 renal pelvis carcinoma 10.0 HCK KRT7 PAX8
46 cutaneous mucoepidermoid carcinoma 10.0 CRTC1 KRT7 MAML2
47 warthin tumor 10.0 CRTC1 KRT7 MAML2
48 lipoadenoma 10.0 CRTC1 KRT7 MAML2
49 biliary papillomatosis 10.0 KRT7 MUC6
50 pleomorphic liposarcoma 10.0 CDKN2A PDGFRA

Graphical network of the top 20 diseases related to Cervical Adenosquamous Carcinoma:



Diseases related to Cervical Adenosquamous Carcinoma

Symptoms & Phenotypes for Cervical Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.5 EGFR
2 Decreased viability GR00173-A 10.5 PDGFRA
3 Decreased viability GR00221-A-1 10.5 CDKN2A EGFR HCK KDR PDGFRA
4 Decreased viability GR00221-A-2 10.5 HCK KDR
5 Decreased viability GR00221-A-3 10.5 CDKN2A KDR PDGFRA
6 Decreased viability GR00221-A-4 10.5 CDKN2A EGFR HCK KDR PDGFRA
7 Decreased viability GR00402-S-2 10.5 CDKN2A EGFR HCK KDR PDGFRA
8 Reduced mammosphere formation GR00396-S 9.43 EGFR KDR KRT7 NOTCH1 PAX8 PTGS2
9 Synthetic lethal with gemcitabine GR00225-A 8.8 CDKN2A HCK KDR

MGI Mouse Phenotypes related to Cervical Adenosquamous Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CDKN2A CRTC1 EGFR HCK HNF1B KDR
2 growth/size/body region MP:0005378 10.18 CDKN2A CRTC1 EGFR HCK HNF1B KDR
3 endocrine/exocrine gland MP:0005379 10.15 CDKN2A CRTC1 EGFR HCK HNF1B NOTCH1
4 cardiovascular system MP:0005385 10.13 CDKN2A EGFR HCK KDR NOTCH1 PAX8
5 embryo MP:0005380 10.11 CDKN2A EGFR HNF1B KDR NOTCH1 PAX8
6 immune system MP:0005387 10.09 CDKN2A CRTC1 EGFR HCK HNF1B KDR
7 muscle MP:0005369 9.91 CDKN2A EGFR HNF1B KDR NOTCH1 PDGFRA
8 liver/biliary system MP:0005370 9.88 CDKN2A EGFR HNF1B KDR NOTCH1 PTGS2
9 neoplasm MP:0002006 9.8 CDKN2A EGFR HCK NOTCH1 PDGFRA PTGS2
10 no phenotypic analysis MP:0003012 9.73 CDKN2A EGFR KDR PAX8 PDGFRA PTGS2
11 renal/urinary system MP:0005367 9.7 EGFR HNF1B KRT7 NOTCH1 PAX8 PDGFRA
12 respiratory system MP:0005388 9.5 CDKN2A EGFR HCK KDR NOTCH1 PDGFRA
13 skeleton MP:0005390 9.23 CDKN2A EGFR HCK KDR NOTCH1 PAX8

Drugs & Therapeutics for Cervical Adenosquamous Carcinoma

Drugs for Cervical Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Vinblastine Approved Phase 3 865-21-4 241903 13342
11
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
12
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
13
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
14
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
15
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
16
Ifosfamide Approved Phase 3 3778-73-2 3690
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antibodies Phase 3,Phase 2,Phase 1
23 Immunoglobulins Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
26 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
27 Immunoglobulin G Phase 3,Phase 2,Phase 1
28 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
29 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
30 Mitogens Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38
Isophosphamide mustard Phase 3 0
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
40 Folic Acid Antagonists Phase 3,Phase 2
41 Anti-Bacterial Agents Phase 3,Phase 2
42 Alkylating Agents Phase 3,Phase 2
43 Vitamin B Complex Phase 3,Phase 2
44 Vitamin B9 Phase 3,Phase 2
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2
46 Dermatologic Agents Phase 3
47 Antineoplastic Agents, Alkylating Phase 3,Phase 2
48 Folate Phase 3,Phase 2
49 Mitomycins Phase 3
50 Antibiotics, Antitubercular Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
5 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
9 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
10 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
11 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
12 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
13 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
14 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
15 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
16 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
17 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
18 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
19 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
20 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
21 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
22 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
23 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
24 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
25 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
26 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
27 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
28 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
29 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
30 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
31 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
32 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
33 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
34 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
35 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
36 Radiation Therapy in Treating Patients With Cervical Cancer Completed NCT00278304 Phase 2
37 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00101192 Phase 2 cisplatin
38 Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
39 Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
40 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
41 Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
42 Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
43 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 2 Cisplatin;Triapine
44 Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin
45 Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Active, not recruiting NCT01266460 Phase 2
46 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Active, not recruiting NCT01267253 Phase 2 Brivanib Alaninate
47 Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting NCT02257528 Phase 2
48 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Active, not recruiting NCT02921269 Phase 2 Atezolizumab
49 ADXS11-001 High Dose HPV+ Cervical Cancer Active, not recruiting NCT02164461 Phase 1, Phase 2
50 Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Active, not recruiting NCT01230996 Phase 1, Phase 2 Cisplatin

Search NIH Clinical Center for Cervical Adenosquamous Carcinoma

Genetic Tests for Cervical Adenosquamous Carcinoma

Anatomical Context for Cervical Adenosquamous Carcinoma

MalaCards organs/tissues related to Cervical Adenosquamous Carcinoma:

41
Cervix, Lung, Kidney, Bone, Breast, Salivary Gland, Appendix

Publications for Cervical Adenosquamous Carcinoma

Articles related to Cervical Adenosquamous Carcinoma:

(show all 11)
# Title Authors Year
1
Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases. ( 30258209 )
2018
2
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
3
A case of melanocytic cervical adenosquamous carcinoma complicated with Cushing's syndrome. ( 29767880 )
2017
4
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
5
Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. ( 22497449 )
2012
6
Duodenal metastasis of cervical adenosquamous carcinoma. ( 22387251 )
2012
7
Cutaneous metastases of cervical adenosquamous carcinoma. ( 20633787 )
2010
8
Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. ( 19727809 )
2009
9
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. ( 19563658 )
2009
10
Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. ( 17666630 )
2007
11
Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. ( 10684719 )
2000

Variations for Cervical Adenosquamous Carcinoma

Expression for Cervical Adenosquamous Carcinoma

Search GEO for disease gene expression data for Cervical Adenosquamous Carcinoma.

Pathways for Cervical Adenosquamous Carcinoma

Pathways related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 CDKN2A EGFR HCK PDGFRA PTGS2
2
Show member pathways
12.66 EGFR HCK KDR PDGFRA PTGS2
3
Show member pathways
12.57 EGFR KDR MAML2 NOTCH1 PDGFRA PTGS2
4
Show member pathways
12.55 CDKN2A EGFR KDR NOTCH1 PDGFRA
5 12.15 CDKN2A EGFR NOTCH1 PAX8 PDGFRA PTGS2
6 12.03 CDKN2A EGFR NOTCH1 PDGFRA PTGS2
7 11.84 HNF1B KDR NOTCH1
8 11.79 EGFR HCK KDR PDGFRA
9 11.73 CDKN2A EGFR PDGFRA
10 11.36 KDR NOTCH1 PDGFRA
11 11.32 CDKN2A EGFR PDGFRA
12 11.26 KDR MAML2 NOTCH1
13 11.17 EGFR KDR PDGFRA
14 10.93 KDR PDGFRA
15 10.87 KDR NOTCH1 PDGFRA PTGS2

GO Terms for Cervical Adenosquamous Carcinoma

Cellular components related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.4 CDKN2A CRTC1 EGFR HCK HNF1B KDR
2 receptor complex GO:0043235 9.26 EGFR KDR NOTCH1 PDGFRA

Biological processes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.99 EGFR HCK KDR NOTCH1 PAX8 PDGFRA
2 positive regulation of transcription, DNA-templated GO:0045893 9.97 CDKN2A EGFR HNF1B NOTCH1 PAX8
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 CDKN2A CRTC1 EGFR HNF1B MAML2 NOTCH1
4 viral process GO:0016032 9.85 CRTC1 HCK KDR KRT7 PDGFRA
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.84 EGFR KDR NOTCH1 PDGFRA
6 positive regulation of cell migration GO:0030335 9.8 EGFR KDR NOTCH1 PDGFRA
7 positive regulation of MAPK cascade GO:0043410 9.79 EGFR KDR PDGFRA
8 response to organic cyclic compound GO:0014070 9.79 EGFR HNF1B PTGS2
9 Notch signaling pathway GO:0007219 9.77 HNF1B MAML2 NOTCH1
10 negative regulation of signal transduction GO:0009968 9.76 EGFR KDR PDGFRA
11 lung development GO:0030324 9.75 EGFR NOTCH1 PDGFRA
12 peptidyl-tyrosine phosphorylation GO:0018108 9.73 EGFR HCK KDR PDGFRA
13 liver development GO:0001889 9.72 EGFR HNF1B NOTCH1
14 protein autophosphorylation GO:0046777 9.71 EGFR HCK KDR PDGFRA
15 negative regulation of apoptotic process GO:0043066 9.63 EGFR HCK HNF1B KDR PDGFRA PTGS2
16 embryonic digestive tract morphogenesis GO:0048557 9.61 HNF1B PDGFRA
17 positive regulation of transcription of Notch receptor target GO:0007221 9.6 MAML2 NOTCH1
18 somatic stem cell division GO:0048103 9.56 CDKN2A NOTCH1
19 mesonephric tubule development GO:0072164 9.52 HNF1B PAX8
20 pronephros development GO:0048793 9.48 HNF1B PAX8
21 peptidyl-tyrosine autophosphorylation GO:0038083 9.43 EGFR HCK KDR
22 positive regulation of cell proliferation GO:0008284 9.43 EGFR HCK KDR NOTCH1 PDGFRA PTGS2
23 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.37 HNF1B PAX8
24 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 8.92 EGFR HCK KDR PDGFRA

Molecular functions related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.56 EGFR KDR NOTCH1 PDGFRA
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 EGFR KDR PDGFRA
3 vascular endothelial growth factor-activated receptor activity GO:0005021 9.32 KDR PDGFRA
4 vascular endothelial growth factor binding GO:0038085 8.96 KDR PDGFRA
5 protein tyrosine kinase activity GO:0004713 8.92 EGFR HCK KDR PDGFRA

Sources for Cervical Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....